VIDEO: Reviewing uses of JAK2 inhibitors in myelofibrosis

ByJohn O. Mascarenhas, MD

ByMarley V. Ghizzone

Fact checked byMindy Valcarcel, MS

John O. Mascarenhas, MD, spoke with Healio about takeaways from a presentation examining ways to optimize the currently available JAK2 inhibitors for the treatment of myelofibrosis.

The talk, given by Srdan Verstovsek, MD, PhD, was presented at 14th International Congress on Myeloproliferative Neoplasms.

“It provides a sense of niches that these approved drugs, JAK inhibitors, can fill,” Mascarenhas, professor of medicine at Icahn School of Medicine at Mount Sinai, director of Center of Excellence for Blood Cancer and Myeloid Disorders, and member of Tisch Cancer Institute, said.

Reference:

Verstovsek S. Optimizing current JAK2 inhibitors in myelofibrosis. Presented at: 14th International Congress on Myeloproliferative Neoplasms; Oct. 27-28, 2022; Brooklyn, New York.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Mascarenhas reports serving as a consultant for AbbVie, Bristol Myers Squibb, Celgene, Constellation, CTI Biopharma, Galecto, Geron, GSK, Incyte, Kartos, Karyopharm, Novartis, PharmaEssentia, Roche and Sierra Oncology; and receiving funding paid to his institution from AbbVie, Bristol Myers Squibb, Celgene, CTI Biopharma, Geron, Incyte, Kartos, Merck, Novartis, PharmaEssentia and Roche.

Discoveries in Myeloproliferative Neoplasms

Read more

VIDEO: Reviewing uses of JAK2 inhibitors in myelofibrosis

Reference:

Related Content